Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Phoenix, Arizona

Phase 3 cancer trials in Phoenix, AZ

55 Phase 3 cancer studies are recruiting participants at sites in Phoenix as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Phoenix at a glance

Breast cancer studies recruiting in Phoenix

Basic details from each study's public record (the 30 most recently updated of 55). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mayo Clinic Cancer Center ( Site 0034)
    Registry record
    NCT06966700 · updated
  2. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    • Phase 3
    • Ages 18 to 60
    • Female participants
    Sponsor
    NRG Oncology
    Study sites
    Cancer Center at Saint Joseph's · Mayo Clinic Hospital in Arizona
    Registry record
    NCT05879926 · updated
  3. E-Mindfulness Approaches for Living After Breast Cancer

    • Phase 3
    • Ages 18 to 50
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    Mayo Clinic Hospital in Arizona
    Registry record
    NCT06748222 · updated
  4. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    The Dignity Health Cancer Institute
    Registry record
    NCT06790693 · updated
  5. The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    American Society of Clinical Oncology
    Study site
    Ironwood Cancer & Research Centers
    Registry record
    NCT06377852 · updated
  6. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Ironwood Cancer & Research Centers
    Registry record
    NCT07062965 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Phoenix, AZ on ClinicalTrials.gov.

Lung cancer studies recruiting in Phoenix

  1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT06767514 · updated
  2. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Mayo Clinic in Arizona - Phoenix
    Registry record
    NCT07063745 · updated
  3. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Cancer Center at Saint Joseph's
    Registry record
    NCT04181060 · updated
  4. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Banner University Medical Center Phoenix
    Registry record
    NCT06119581 · updated
  5. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mayo Clinic in Arizona - Phoenix ( Site 0147)
    Registry record
    NCT06170788 · updated
  6. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT06627647 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Phoenix, AZ on ClinicalTrials.gov.

Prostate cancer studies recruiting in Phoenix

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Cancer Center at Saint Joseph's
    Registry record
    NCT04423211 · updated
  2. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mayo Clinic in Arizona - Phoenix ( Site 0044)
    Registry record
    NCT06925737 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Phoenix, AZ on ClinicalTrials.gov.

Melanoma studies recruiting in Phoenix

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Cancer Center at Saint Joseph's
    Registry record
    NCT07068074 · updated
  2. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    Mayo Clinic
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Phoenix, AZ on ClinicalTrials.gov.

Lymphoma studies recruiting in Phoenix

  1. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Mayo Clinic Hospital in Arizona
    Registry record
    NCT06337318 · updated
  2. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Nuvation Bio Inc.
    Study sites
    Mayo Clinic - Arizona · St. Joseph's Hospital and Medical Center
    Registry record
    NCT05303519 · updated
  3. A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051)
    Registry record
    NCT06136559 · updated
  4. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Mayo Clinic Hospital in Arizona
    Registry record
    NCT06724237 · updated
  5. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167)
    Registry record
    NCT06717347 · updated
  6. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Cancer Center at Saint Joseph's · Phoenix Childrens Hospital
    Registry record
    NCT05675410 · updated
  7. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Saint Joseph's Hospital and Medical Center
    Registry record
    NCT07215910 · updated
  8. IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Ono Pharmaceutical Co., Ltd.
    Study site
    Mayo Clinic Cancer Center
    Registry record
    NCT07104032 · updated
  9. A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

    • Phase 3
    • Ages 18 to 130
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT06549595 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Phoenix, AZ on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Phoenix

  1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immuneering Corporation
    Study site
    City of Hope
    Registry record
    NCT07562152 · updated
  2. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Mayo Clinic Arizona
    Registry record
    NCT07621718 · updated
  3. Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Mayo Clinic Arizona
    Registry record
    NCT07805954 · updated
  4. Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Mayo Clinic Hospital
    Registry record
    NCT06943755 · updated
  5. Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Mayo Clinic
    Registry record
    NCT07252232 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Phoenix, AZ on ClinicalTrials.gov.

Ask about studies near Phoenix

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call